MRK Merck & Co Inc

Price (delayed)

$81.15

Market cap

$205.31B

P/E Ratio

17.84

Dividend/share

$2.48

EPS

$4.55

Enterprise value

$226.7B

Sector: Healthcare
Industry: Drug Manufacturers - General

Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American multinational pharmaceutical company and one of the largest pharmaceutical companies in the ...

Highlights

The P/E is 57% lower than the 5-year quarterly average of 41.6 and 11% lower than the last 4 quarters average of 20.0
The EPS has grown by 26% YoY and by 10% from the previous quarter
MRK's debt is up by 10% year-on-year but it is down by 7% since the previous quarter
MRK's quick ratio is down by 8% since the previous quarter and by 3.8% year-on-year

Key stats

What are the main financial stats of MRK
Market
Shares outstanding
2.53B
Market cap
$205.31B
Enterprise value
$226.7B
Valuations
Price to earnings (P/E)
17.84
Price to book (P/B)
7.03
Price to sales (P/S)
4.33
EV/EBIT
16.72
EV/EBITDA
13.17
EV/Sales
4.79
Earnings
Revenue
$47.35B
EBIT
$13.56B
EBITDA
$17.21B
Free cash flow
$6.73B
Per share
EPS
$4.55
Free cash flow per share
$2.66
Book value per share
$11.54
Revenue per share
$18.72
TBVPS
$20.91
Balance sheet
Total assets
$89.8B
Total liabilities
$60.53B
Debt
$28.74B
Equity
$29.19B
Working capital
$6.17B
Liquidity
Debt to equity
0.98
Current ratio
1.3
Quick ratio
0.77
Net debt/EBITDA
1.24
Margins
EBITDA margin
36.4%
Gross margin
71.2%
Net margin
24.3%
Operating margin
26.9%
Efficiency
Return on assets
13.2%
Return on equity
42.3%
Return on invested capital
27.6%
Return on capital employed
19.5%
Return on sales
28.6%
Dividend
Dividend yield
3.06%
DPS
$2.48
Payout ratio
54.5%

MRK stock price

How has the Merck stock price performed over time
Intraday
0.21%
1 week
-2.67%
1 month
1.26%
1 year
-5.62%
YTD
-0.79%
QTD
-0.79%

Financial performance

How have Merck's revenue and profit performed over time
Revenue
$47.35B
Gross profit
$33.73B
Operating income
$12.72B
Net income
$11.52B
Gross margin
71.2%
Net margin
24.3%
The net income is up by 24% year-on-year and by 10% since the previous quarter
MRK's net margin is up by 20% year-on-year and by 9% since the previous quarter
Merck's operating income has increased by 8% YoY and by 6% from the previous quarter
Merck's operating margin has increased by 6% QoQ and by 5% YoY

Growth

What is Merck's growth rate over time

Valuation

What is Merck stock price valuation
P/E
17.84
P/B
7.03
P/S
4.33
EV/EBIT
16.72
EV/EBITDA
13.17
EV/Sales
4.79
The P/E is 57% lower than the 5-year quarterly average of 41.6 and 11% lower than the last 4 quarters average of 20.0
The EPS has grown by 26% YoY and by 10% from the previous quarter
The price to book (P/B) is 21% higher than the 5-year quarterly average of 5.8 but 9% lower than the last 4 quarters average of 7.7
Merck's equity has increased by 9% YoY and by 6% from the previous quarter
The revenue has grown by 3% YoY

Efficiency

How efficient is Merck business performance
Merck's ROE has increased by 23% YoY and by 8% from the previous quarter
The ROIC rose by 21% YoY and by 6% QoQ
The company's return on assets rose by 18% YoY and by 8% QoQ
The ROS has grown by 15% YoY and by 8% from the previous quarter

Dividends

What is MRK's dividend history
DPS
$2.48
Dividend yield
3.06%
Payout ratio
54.5%
Recent dividends

Financial health

How did Merck financials performed over time
The total assets is 48% more than the total liabilities
MRK's quick ratio is down by 8% since the previous quarter and by 3.8% year-on-year
Merck's total liabilities has increased by 7% YoY but it has decreased by 3.7% QoQ
MRK's debt is up by 10% year-on-year but it is down by 7% since the previous quarter
Merck's equity has increased by 9% YoY and by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.